>
Tina Peters, granted clemency by Colorado's Dem governor
Tulsi Gabbard at center of explosive CIA claim as JFK and MKUltra files 'vanish from her office*
Bessent Says US, China To Launch AI Safety Talks After Trump-Xi Meeting In Beijing
Cuba Depletes Fuel As Blackouts Worsen, Putting Havana's Communists Under Pressure...
US To Develop Small Modular Nuclear Reactors For Commercial Shipping
New York Mandates Kill Switch and Surveillance Software in Your 3D Printer ...
Cameco Sees As Many As 20 AP1000 Nuclear Reactors On The Horizon
His grandparents had heart disease.
At 11, Laurent Simons decided he wanted to fight aging.
Mayo Clinic's AI Can Detect Pancreatic Cancer up to 3 Years Before Diagnosis–When Treatment...
A multi-terrain robot from China is going viral, not because of raw speed or power...
The World's Biggest Fusion Reactor Just Hit A Milestone
Wow. Researchers just built an AI that can control your body...
Google Chrome silently installs a 4 GB AI model on your device without consent
The $5 Battery That Never Dies - Edison Buried This 100 Years Ago

A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.